NCT02870582View on ClinicalTrials.gov

Donafenib for Previously Treated Metastatic Colorectal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

536

Participants

Timeline

Start Date

December 28, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Donafenib

treatment drug

DRUG

Placebo

Best support treatment

Trial Locations (2)

100071

the 307th Hospital of Chinese People's Liberation Army, Beijing

610041

West China Hospital Sichuan, Chengdu

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT02870582 - Donafenib for Previously Treated Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter